Treatment Information

Back

Ovarian Cancer treatment details. Biologic therapy.

University Hospital of Gieben and Marburg, Marburg, Germany.

Survival: monthsCountry:Germany
Toxiciy Grade:4City/State/Province:Marburg
Treatments:Biologic therapyHospital:University Hospital of Gieben and Marburg
Drugs:Journal:Link
Date:Sep 2012

Description:

Patients:
This phase 2 study involved 37 ovarian cancer patients who had recurrence of their cancer following previous platinum-based chemotherapy. The average patient age was 58.5 years.

Treatment:
Patients were treated with the biologic therapy agent sunitinib, which is a tyrosine kinase inhibitor that causes an inhibition of tumor growth.

Toxicities:
The most severe toxicities were of grade 4. Grade 3-4 toxicities included thrombocytopenia, neutropenia, and leukopenia.

Results:
The median overall survival was 13.7 months.

Support:
This study was supported by Pfizer.

Correspondence: Dr. K. H. Baumann; email: [email protected]



Back